Akebia Therapeutics (AKBA) Gross Profit (2018 - 2025)
Historic Gross Profit for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $49.4 million.
- Akebia Therapeutics' Gross Profit rose 11224.48% to $49.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.8 million, marking a year-over-year increase of 33323.84%. This contributed to the annual value of $97.0 million for FY2024, which is 25121.51% up from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' Gross Profit is $49.4 million, which was up 11224.48% from $52.6 million recorded in Q2 2025.
- Akebia Therapeutics' Gross Profit's 5-year high stood at $107.8 million during Q2 2022, with a 5-year trough of -$147.1 million in Q4 2023.
- Its 5-year average for Gross Profit is $23.2 million, with a median of $24.0 million in 2023.
- As far as peak fluctuations go, Akebia Therapeutics' Gross Profit surged by 2568110.05% in 2022, and later plummeted by 34842.01% in 2023.
- Quarter analysis of 5 years shows Akebia Therapeutics' Gross Profit stood at $10.0 million in 2021, then skyrocketed by 489.16% to $59.2 million in 2022, then plummeted by 348.42% to -$147.1 million in 2023, then soared by 117.77% to $26.1 million in 2024, then skyrocketed by 88.98% to $49.4 million in 2025.
- Its Gross Profit was $49.4 million in Q3 2025, compared to $52.6 million in Q2 2025 and $49.7 million in Q1 2025.